# Health-claim substantiation (EFSA 13/14) A thin category — clinical and scientific evidence dossier preparation to substantiate a health claim under EFSA's Article 13/14 framework — three confirmed vendors spanning generic testing/certification, dedicated EU regulatory consulting, and North American clinical-execution services. Source: https://en.bioecon.ru/technology/health-claim-substantiation-efsa/ Updated: 2026-08-21 ## Overview and value chain Markers: [EC: EU Regulation 1924/2006 (Nutrition and Health Claims) | OECD: food-systems, cross-cutting | Regulator: FDA (USA)] Health-claim substantiation prepares the scientific and clinical evidence dossier required to support a food, supplement, or nutraceutical health claim under the EU's Article 13/14 framework (EFSA Regulation 1924/2006) or equivalent national health-claim regimes. A health claim — "supports immune function," "reduces cholesterol absorption" — cannot be marketed in the EU without a substantiated, EFSA-reviewed evidence base, making this a genuine regulatory-compliance service distinct from general food-safety testing. The confirmed vendor base spans a range of positioning: a large generic testing/certification conglomerate with nutrition-science capability, a dedicated EU health-claim regulatory consultancy, and a North American firm spanning regulatory strategy through clinical trial execution. The key directions of health-claim substantiation are: 1. **Article 13/14 dossier preparation:** compiling the scientific evidence base required for EFSA's general-function (Article 13) or disease-risk-reduction (Article 14) health-claim categories. 2. **Clinical trial design and execution for claim support:** running the human clinical studies needed to generate claim-supporting evidence where existing literature is insufficient. 3. **Regulatory strategy from concept to filing:** advising a client from initial claim concept through the full EFSA submission and review process. 4. **Cross-jurisdictional claim harmonization:** adapting a substantiated claim for multiple regulatory regimes (EU, US FDA, other national frameworks) from a shared evidence base. ### Sectoral value chain ``` [Claim concept development] ──> [Evidence gap analysis] ──> [Clinical trial execution] ──> [Dossier compilation] │ (EFSA submission) │ ▼ [Claim market authorization] <─── [Regulatory review response] <─────┘ ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **Claim concept development** | Defining the specific health claim the client wants to substantiate | **In:** product formulation, marketing goals.
**Out:** a defined claim concept. | | **Evidence gap analysis** | Assessing existing scientific literature against the claim to identify evidence gaps | **In:** claim concept, literature review.
**Out:** an evidence gap analysis. | | **Clinical trial execution** | Running human clinical studies to fill identified evidence gaps | **In:** gap analysis, trial protocol.
**Out:** clinical trial data. | | **Dossier compilation** | Compiling the full scientific and clinical evidence base into an EFSA-format dossier | **In:** literature, clinical data.
**Out:** a submission-ready dossier. | | **EFSA submission/review response** | Submitting the dossier and responding to EFSA's scientific review questions | **In:** dossier.
**Out:** a review response record. | | **Claim market authorization** | The claim receives EFSA authorization and can be used in EU marketing | **In:** review response.
**Out:** an authorized health claim. | Cross-cutting technologies of the sector: - **Systematic literature review methodology:** structured evidence-review techniques required to assess a claim's existing scientific support. - **Clinical trial design for regulatory claims:** trial design specifically oriented toward generating EFSA-acceptable evidence rather than general research publication. - **Regulatory dossier formatting expertise:** the specific documentation and formatting knowledge required for an EFSA-compliant submission. --- ## US The US has one confirmed vendor spanning regulatory strategy through clinical execution. ### Regulatory strategy to clinical execution, certification and consumer trust - **Nutrasource (SGS Nutrasource):** confirmed via its own domain's case coverage of advancing CBD innovation through regulatory-strategy-to-clinical-execution work with DSM-Firmenich, and independent Nutritional Outlook coverage of how the SGS Nutrasource brand serves the industry through certifications, clinical trials, and consumer-trust practice. --- ## CN No Chinese vendor with a dedicated, confirmed health-claim-substantiation practice was found on a live screen. ### No confirmed dedicated vendor - **Market context:** this article found no Chinese company with confirmed, on-topic evidence of a dedicated EFSA-style health-claim-substantiation practice. - **Reopen condition:** if a Chinese vendor selling confirmed health-claim-substantiation services surfaces on a future screen, this section should be revised and the company added to the table. --- ## EU The EU has two confirmed vendors, spanning a large generic testing/certification conglomerate and a dedicated regulatory consultancy. ### Nutrition-science testing capability, dedicated EU health-claim consulting - **Intertek (UK):** a large testing, inspection, and certification conglomerate with confirmed nutrition-science and EFSA-relevant capability, evidenced via its own LinkedIn coverage referencing nutrition science and EFSA specifically alongside independent food/pharma-law coverage of health-claims regulation. - **Care Europe (Belgium):** confirmed via its own blog coverage of nutraceutical regulatory consulting for EU market entry, alongside a third-party regulatory-services page referencing its health-claims work — a food-regulatory consultancy broader than health-claims exclusively, but with genuine claim-substantiation-relevant work documented. --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **Nutrasource** | 🇨🇦 Canada | *Regulatory strategy to clinical execution* | Certifications, clinical trials, and consumer-trust practice for health-claim support | Active, confirmed via own-domain case coverage | | **Intertek** | 🇬🇧 UK | *Nutrition-science testing and certification* | Large TIC conglomerate with EFSA-relevant nutrition-science capability | Active, confirmed via own LinkedIn/nutrition-science content | | **Care Europe** | 🇧🇪 Belgium | *Nutraceutical regulatory consulting* | EU market-entry regulatory strategy including health-claims work | Active, confirmed via own blog coverage | --- ## Tech stack and innovations The category's core capability is scientific and regulatory expertise applied to evidence generation and dossier preparation, rather than a physical technology. 1. **Regulatory-strategy-to-clinical-execution integration:** - Nutrasource's documented work with DSM-Firmenich spans from initial regulatory strategy through actual clinical trial execution, reflecting a full-service model rather than dossier-writing alone. 2. **Large-conglomerate nutrition-science capability:** - Intertek's scale as a testing/certification conglomerate gives it broad laboratory and scientific-review capacity applicable to health-claim substantiation, distinct from a boutique regulatory consultancy's narrower focus. 3. **Dedicated EU market-entry regulatory strategy:** - Care Europe's positioning specifically around EU nutraceutical market entry reflects the jurisdiction-specific expertise health-claim substantiation requires, since EFSA's Article 13/14 framework is distinct from other national regimes. --- ## Value chains and production pipelines ### Industrial pipeline of an EFSA health-claim dossier (EU Regulation 1924/2006) ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. Claim concept development │ ───> │ 2. Evidence gap analysis │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. Dossier compilation │ <─── │ 3. Clinical trial execution │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. EFSA submission/review response │ ───> │ 6. Claim market authorization │ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: Claim concept development The client and consultant define the specific health claim to be substantiated, tied to the product's formulation and marketing goals. #### Stage 2: Evidence gap analysis Existing scientific literature is reviewed against the claim to identify what evidence already exists and what gaps remain. #### Stage 3: Clinical trial execution Where evidence gaps exist, human clinical studies are designed and run specifically to generate claim-supporting data. #### Stage 4: Dossier compilation The full scientific and clinical evidence base is compiled into a formatted dossier meeting EFSA's Article 13/14 submission requirements. #### Stage 5: EFSA submission/review response The dossier is submitted to EFSA, and the consultancy responds to any scientific review questions raised during assessment. #### Stage 6: Claim market authorization Once authorized, the claim can be used in EU product marketing, completing the regulatory pathway from concept to market. ---